trimetazidine has been researched along with cardiovascular agents in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 15 (41.67) | 29.6817 |
| 2010's | 15 (41.67) | 24.3611 |
| 2020's | 5 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chirkov, YY; Chirkova, LP; Horowitz, JD; Kennedy, JA; Murphy, GA; Willoughby, SR | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Arkharov, IV; Burbello, AT; Makhnov, AP; Shabrov, AV | 1 |
| Hill, JA; Schofield, RS | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Pauly, DF; Pepine, CJ | 1 |
| McCullough, PA | 1 |
| Inglis, S; Stewart, S | 1 |
| Glonti, TG; Gorgoshidze, ML; Svanidze, TD; Tsintsadze, IN | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Iushchuk, EN; Khadzegova, AB; Sadulaeva, IA; Shkol'nik, EL; Vakhromeeva, MN; Vasiuk, IuA; Vit'ko, NK | 1 |
| Fischer, T | 1 |
| Ashrafian, H; Frenneaux, MP; Williams, L | 1 |
| Onay-Besikci, A; Ozkan, SA | 1 |
| Banach, M; Goch, A; Mikhailidis, DP; Rosano, GM; Rysz, J | 1 |
| Arioli, F; Bassanelli, G; Fragasso, G; Margonato, A; Salerno, A; Spoladore, R | 1 |
| Chirkov, YY; Horowitz, JD; Kennedy, JA; Sverdlov, AL | 1 |
| Antony, R; Dargie, HJ | 1 |
| Banach, M; Chrusciel, P; Rysz, J | 1 |
| Castriota, F; Cremonesi, A; De Luca, G; Fattori, R; Lupi, A; Marino, PN; Mirabella, F; Parisi, R; Rognoni, A; Secco, GG | 1 |
| Amaral, N; Okonko, DO | 1 |
| Ambrosio, G; Grant, PJ; Tamargo, J | 1 |
| Ermolenko, AA; Statsenko, ME; Turkina, SV | 1 |
| Colombo, A; Fragasso, G; Fumero, A; Giannini, F; Godino, C; Maranta, F; Margonato, A; Oppizzi, M; Slavich, M | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
| Chen, A; Chen, M; Chen, X; Dai, W; Dong, Q; Li, W; Li, X; Ou, C; Shen, Y | 1 |
| Glezer, M | 1 |
| Balla, C; Ferrari, R; Pavasini, R | 1 |
| Giannitsi, S; Kallistratos, MS; Manolis, AJ; Poulimenos, LE; Tsinivizov, P | 1 |
| Lu, X; Ma, X; Wang, J; Wen, J; Yang, Y; Zhang, L; Zhao, Y | 1 |
| Glezer, MG; Vygodin, VA | 1 |
| He, J; Jin, C; Li, Y; Luan, Y; Wang, M; Wu, L; Zhang, W | 1 |
| Chen, W; Wang, C; Yang, P; Yu, M | 1 |
| Tolunay, H | 1 |
| Bai, J; Bai, N; Chi, J; Ding, X; Liu, J; Nie, C; Yang, W; Zhan, C; Zheng, M | 1 |
| Cesar, LAM; Dourado, LOC; Gowdak, LHW; Grobe, SF; Moreno, CPD | 1 |
22 review(s) available for trimetazidine and cardiovascular agents
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
Role of metabolically active drugs in the management of ischemic heart disease.
Topics: Acetanilides; Animals; Cardiovascular Agents; Carnitine; Clinical Trials as Topic; Dichloroacetic Acid; Energy Metabolism; Fatty Acids; Glucose; Humans; Insulin; Myocardial Ischemia; Myocardium; Piperazines; Potassium; Ranolazine; Trimetazidine | 2001 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Ischemic heart disease: metabolic approaches to management.
Topics: Acetanilides; Cardiovascular Agents; Carnitine; Dichloroacetic Acid; Energy Metabolism; Humans; Myocardial Ischemia; Oxidation-Reduction; Piperazines; Ranolazine; Ribose; Trimetazidine | 2004 |
Chronic angina: new medical options for treatment.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2005 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
[New possibilities in the pharmacologic prevention of age-related macular degeneration].
Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular Degeneration; Oxidative Stress; Platelet Aggregation Inhibitors; Primary Prevention; Risk Factors; Trimetazidine; Vasodilation; Vasodilator Agents | 2008 |
Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.
Topics: Animals; Antioxidants; Cardiovascular Agents; Chemistry Techniques, Analytical; Chromatography; Coronary Circulation; Coronary Vessels; Electrochemistry; Energy Metabolism; Flow Injection Analysis; Heart Diseases; Humans; Ischemia; Luminescent Measurements; Myocardial Contraction; Myocardium; Reactive Oxygen Species; Spectrophotometry; Trimetazidine | 2008 |
The role of trimetazidine after acute myocardial infarction.
Topics: Acute Coronary Syndrome; Angina Pectoris; Cardiovascular Agents; Energy Metabolism; Humans; Myocardial Infarction; Myocardium; Practice Guidelines as Topic; Treatment Outcome; Trimetazidine | 2008 |
Metabolic therapy of heart failure.
Topics: Animals; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Fatty Acids, Nonesterified; Heart Failure; Humans; Myocardium; Perhexiline; Trimetazidine | 2008 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardium; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2010 |
Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Heart Failure; Humans; Peripheral Arterial Disease; Trimetazidine | 2014 |
Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization.
Topics: Angina, Stable; Animals; Benzazepines; Cardiovascular Agents; Humans; Ivabradine; Nicorandil; Percutaneous Coronary Intervention; Ranolazine; Trimetazidine | 2015 |
Metabolic abnormalities of the heart in type II diabetes.
Topics: Antioxidants; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Fatty Acids; Glucose; Humans; Mitochondria, Heart; Myocardium; Organophosphorus Compounds; Oxidative Phosphorylation; Oxidative Stress; Perhexiline; Ranolazine; Trimetazidine; Ubiquinone | 2015 |
Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Topics: Animals; Cardiovascular Agents; Coronary Artery Disease; Diabetes Mellitus; Humans; Ranolazine; Trimetazidine; Vasodilator Agents | 2016 |
[Unsolved problems of cytoprotective therapy in patients with coronary heart disease].
Topics: Cardiotonic Agents; Cardiovascular Agents; Coronary Disease; Humans; Methylhydrazines; Trimetazidine | 2015 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
Treatment of Angina: Where Are We?
Topics: Adrenergic beta-Antagonists; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Chest Pain; Humans; Ivabradine; Nicorandil; Patient Selection; Practice Guidelines as Topic; Ranolazine; Treatment Outcome; Trimetazidine | 2018 |
Trimetazidine in the Prevention of Tissue Ischemic Conditions.
Topics: Acute Kidney Injury; Animals; Cardiovascular Agents; Contrast Media; Coronary Artery Bypass; Energy Metabolism; Glucose; Humans; Kidney; Myocardial Reperfusion Injury; Myocytes, Cardiac; Percutaneous Coronary Intervention; Risk Factors; Treatment Outcome; Trimetazidine | 2019 |
Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy: A systematic review and meta-analysis.
Topics: Cardiovascular Agents; Drug Therapy, Combination; Drugs, Chinese Herbal; Heart Failure; Humans; Myocardial Ischemia; Randomized Controlled Trials as Topic; Trimetazidine | 2018 |
Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Topics: Biomarkers; Cardiovascular Agents; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Reperfusion Injury; Myocardium; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Recovery of Function; Risk Factors; Stroke Volume; Treatment Outcome; Trimetazidine; Troponin I; Ventricular Function, Left | 2021 |
5 trial(s) available for trimetazidine and cardiovascular agents
| Article | Year |
|---|---|
[Effect of trimetazidine and perindopril on myocardial function and metabolism in patients with low cardiac output during postinfarction period].
Topics: Adult; Aged; Blood Pressure; Cardiac Output, Low; Cardiovascular Agents; Drug Therapy, Combination; Electrocardiography; Energy Metabolism; Fatty Acids, Nonesterified; Glucose; Humans; Infarction; Male; Middle Aged; Myocardial Contraction; Myocardium; Perindopril; Trimetazidine | 2003 |
[Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction].
Topics: Adult; Aged; Cardiovascular Agents; Drug Therapy, Combination; Female; Glucose; Humans; Insulin; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Potassium; Trimetazidine; Vasodilator Agents | 2006 |
[Comparative trial of efficacy of trimethasidine MB and 3-(2,2,2-trimethylhydrasine) propionate dihydrate in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Diuretics; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Positron-Emission Tomography; Trimetazidine; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Cardiovascular Agents; China; Coronary Artery Disease; Female; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Randomized Controlled Trials as Topic; Recovery of Function; Time Factors; Treatment Outcome; Trimetazidine; Ventricular Function, Left; Ventricular Remodeling; Young Adult | 2020 |
Antinociceptive effect of ranolazine and trimetazidine.
Topics: Aged; Aged, 80 and over; Analgesics; Cardiovascular Agents; Female; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2021 |
9 other study(ies) available for trimetazidine and cardiovascular agents
| Article | Year |
|---|---|
Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Topics: Adult; Aged; Amiodarone; Blood Platelets; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Case-Control Studies; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Female; Humans; Male; Middle Aged; Perhexiline; Platelet Aggregation; Trimetazidine; Vasodilator Agents | 1998 |
The pathophysiology of heart failure: a tale of two old paradigms revisited.
Topics: Cardiovascular Agents; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Heart Failure; Humans; Metabolic Networks and Pathways; Perhexiline; Trimetazidine; Vasodilator Agents | 2008 |
Allopurinol for chronic stable angina: old drug, new tricks?
Topics: Allopurinol; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Enzyme Inhibitors; Humans; Trimetazidine; Vasodilator Agents | 2010 |
Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
Topics: Aged; Angina Pectoris; Benzazepines; Cardiovascular Agents; Echocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Ivabradine; Male; Myocardial Ischemia; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Stroke Volume; Systole; Time Factors; Tomography, Emission-Computed, Single-Photon; Trimetazidine; Vasodilator Agents; Ventricular Function, Left | 2016 |
Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Aorta, Abdominal; Arterial Pressure; Cardiovascular Agents; Constriction; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Myocardium; Neuropeptide Y; Oxidative Stress; Rats, Wistar; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Receptors, Neuropeptide Y; Signal Transduction; Trimetazidine; Ventricular Function, Left; Ventricular Remodeling | 2016 |
The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Drug Therapy, Combination; Exercise; Exercise Test; Exercise Tolerance; Female; Humans; Ivabradine; Male; Middle Aged; Nitrates; Prospective Studies; Quality of Life; Research Design; Russia; Time Factors; Trimetazidine; Vasodilator Agents; Walk Test | 2018 |
[Evaluation of the antianginal effectiveness of trimetazidine in a new dosage form for a single dose, depending on the region of the Russian Federation. ODA trial results].
Topics: Aged; Angina, Stable; Cardiovascular Agents; Female; Humans; Male; Russia; Trimetazidine; Vasodilator Agents | 2019 |
Combined Usage of Trimetazidine With 3-Bromopyruvate May Lead to Cardiotoxicity by Activating Oxidative Stress and Apoptosis in Rats.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cardiotoxicity; Cardiovascular Agents; Energy Metabolism; Enzyme Inhibitors; Heart Diseases; Male; Myocytes, Cardiac; Oxidative Stress; Pyruvates; Rats, Wistar; Signal Transduction; Trimetazidine; Ventricular Function, Left | 2021 |
Concomitant Use of Ranolazine and Trimetazidine in Patients with Refractory Angina: An Initial Experience.
Topics: Angina Pectoris; Angina, Stable; Cardiovascular Agents; Humans; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2022 |